MA55766A - Nanoparticules lipidiques - Google Patents
Nanoparticules lipidiquesInfo
- Publication number
- MA55766A MA55766A MA055766A MA55766A MA55766A MA 55766 A MA55766 A MA 55766A MA 055766 A MA055766 A MA 055766A MA 55766 A MA55766 A MA 55766A MA 55766 A MA55766 A MA 55766A
- Authority
- MA
- Morocco
- Prior art keywords
- lipid nanoparticles
- nanoparticles
- lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839452P | 2019-04-26 | 2019-04-26 | |
| US201962867098P | 2019-06-26 | 2019-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55766A true MA55766A (fr) | 2022-03-02 |
Family
ID=72941858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055766A MA55766A (fr) | 2019-04-26 | 2020-04-24 | Nanoparticules lipidiques |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220168222A1 (fr) |
| EP (1) | EP3959314A4 (fr) |
| JP (1) | JP2022530018A (fr) |
| CN (1) | CN114026233A (fr) |
| AU (1) | AU2020262437A1 (fr) |
| CA (1) | CA3137450A1 (fr) |
| MA (1) | MA55766A (fr) |
| WO (1) | WO2020219941A1 (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019376006A1 (en) * | 2018-11-09 | 2021-06-03 | Arbutus Biopharma Corporation | Cationic lipids containing silicon |
| EP4076647A1 (fr) | 2019-12-20 | 2022-10-26 | CureVac AG | Nanoparticules lipidiques pour l'administration d'acides nucléiques |
| US12023376B1 (en) | 2020-04-17 | 2024-07-02 | Triad National Security, Llc | Conserved region T cell vaccines for coronavirus and methods of use |
| JP2023534206A (ja) * | 2020-07-10 | 2023-08-08 | ジェネヴァント サイエンシズ ゲーエムベーハー | 肺に治療薬を送達するための脂質ナノ粒子 |
| EP4189098A1 (fr) | 2020-07-27 | 2023-06-07 | Anjarium Biosciences AG | Compositions de molécules d'adn, leurs procédés de fabrication et leurs procédés d'utilisation |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| JP2023546175A (ja) | 2020-10-14 | 2023-11-01 | ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド | 脂質ナノ粒子製造の方法及びそれに由来する組成物 |
| WO2022099003A1 (fr) | 2020-11-06 | 2022-05-12 | Sanofi | Nanoparticules lipidiques pour l'administration de vaccins à arnm |
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| AU2021403156A1 (en) * | 2020-12-18 | 2023-07-13 | Genevant Sciences Gmbh | Peg lipids and lipid nanoparticles |
| WO2022198229A1 (fr) * | 2021-03-17 | 2022-09-22 | Board Of Regents Of The University Of Nebraska | Formulations de nanoparticules lipidiques et leurs méthodes d'utilisation |
| JP2024516575A (ja) | 2021-04-16 | 2024-04-16 | ジェネンテック， インコーポレイテッド | 最適化されたｔｌｒ７リガンド及びその使用 |
| WO2023031392A2 (fr) | 2021-09-03 | 2023-03-09 | CureVac SE | Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques comprenant de la phosphatidylsérine |
| CA3235493A1 (fr) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vii, Llc | Compositions d'adn et procedes associes |
| KR20230061895A (ko) * | 2021-10-29 | 2023-05-09 | 주식회사 아이큐어비앤피 | 지질 나노입자 및 세포 투과성을 갖는 신규 펩타이드의 복합체 |
| CN117203186A (zh) * | 2022-05-13 | 2023-12-08 | 南方科技大学 | 一种含有二硫键的脂质化合物及其组合物 |
| EP4522650A1 (fr) | 2022-05-13 | 2025-03-19 | BioNTech SE | Compositions d'arn ciblant le vih |
| IL317018A (en) | 2022-05-23 | 2025-01-01 | Logicbio Therapeutics Inc | Garden treatment preparations and methods of using them |
| AU2023275780B2 (en) | 2022-05-25 | 2026-03-05 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2023230295A1 (fr) | 2022-05-25 | 2023-11-30 | BioNTech SE | Compositions d'arn pour l'administration d'antigènes de la variole du singe et méthodes associées |
| EP4518845A1 (fr) | 2022-05-30 | 2025-03-12 | BioNTech SE | Complexes pour l'administration d'acides nucléiques |
| TWI858802B (zh) * | 2022-07-06 | 2024-10-11 | 南韓商綠十字股份有限公司 | 使用陽離子膽固醇用於核酸遞送的局部遞送的脂質納米顆粒 |
| AU2023316579A1 (en) | 2022-07-29 | 2025-02-13 | Fujifilm Corporation | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE |
| WO2024037577A1 (fr) * | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition de nanoparticules lipidiques |
| WO2024057237A1 (fr) | 2022-09-16 | 2024-03-21 | Pfizer Inc. | Nanoparticules lipidiques |
| EP4342460A1 (fr) | 2022-09-21 | 2024-03-27 | NovoArc GmbH | Nanoparticule lipidique avec charge d'acide nucléique |
| CN119095585A (zh) * | 2022-12-21 | 2024-12-06 | 苏州艾博生物科技有限公司 | 包含固醇修饰的磷脂的脂质纳米颗粒 |
| WO2024141955A1 (fr) | 2022-12-28 | 2024-07-04 | BioNTech SE | Compositions d'arn ciblant le vih |
| EP4410316A1 (fr) * | 2023-02-01 | 2024-08-07 | 4basebio UK Ltd | Nanoparticules pour l'administration de charges d'acides nucléiques |
| AU2024217077A1 (en) * | 2023-02-06 | 2025-09-18 | University Of Tennessee Research Foundation | Multi-functional lipid nanoparticles and uses thereof |
| WO2024205499A1 (fr) * | 2023-03-27 | 2024-10-03 | Agency For Science, Technology And Research | Composé pour la préparation de nanoparticules lipidiques encapsulant un agent, composition de nanoparticules comprenant ledit composé et procédés associés |
| WO2024259158A2 (fr) * | 2023-06-13 | 2024-12-19 | Cornell University | Nanoparticules lipidiques pour l'administration de peptides et leurs procédés de fabrication et d'utilisation |
| WO2025027579A2 (fr) | 2023-08-03 | 2025-02-06 | BioNTech SE | Compositions d'arn ciblant le vih |
| WO2025027576A2 (fr) | 2023-08-03 | 2025-02-06 | BioNTech SE | Compositions d'arn ciblant le vih |
| CN121752256A (zh) | 2023-09-01 | 2026-03-27 | 诺沃阿克有限责任公司 | 具有核酸负载物和可电离脂质的脂质纳米颗粒 |
| WO2025124711A1 (fr) | 2023-12-13 | 2025-06-19 | BioNTech SE | Compositions de glycolipides |
| WO2025219570A1 (fr) | 2024-04-17 | 2025-10-23 | Johannes Kepler Universität Linz | Composition pour inhiber la translocation de protéines et procédés l'utilisant |
| WO2025242657A1 (fr) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Blocs et agrégats de construction de lipopeptides |
| GB202408360D0 (en) | 2024-06-11 | 2024-07-24 | Cancer Research Tech Ltd | Tumour sensitisation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016366978B2 (en) * | 2015-12-10 | 2022-07-28 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| MX2018016389A (es) * | 2016-06-30 | 2019-08-16 | Arbutus Biopharma Corp | Composiciones y metodos para suministro de arn mensajero. |
-
2020
- 2020-04-24 EP EP20795521.2A patent/EP3959314A4/fr not_active Withdrawn
- 2020-04-24 JP JP2021562869A patent/JP2022530018A/ja not_active Abandoned
- 2020-04-24 MA MA055766A patent/MA55766A/fr unknown
- 2020-04-24 WO PCT/US2020/029907 patent/WO2020219941A1/fr not_active Ceased
- 2020-04-24 US US17/605,698 patent/US20220168222A1/en not_active Abandoned
- 2020-04-24 CA CA3137450A patent/CA3137450A1/fr active Pending
- 2020-04-24 AU AU2020262437A patent/AU2020262437A1/en not_active Abandoned
- 2020-04-24 CN CN202080046391.4A patent/CN114026233A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220168222A1 (en) | 2022-06-02 |
| WO2020219941A1 (fr) | 2020-10-29 |
| AU2020262437A1 (en) | 2021-12-23 |
| EP3959314A4 (fr) | 2023-02-08 |
| JP2022530018A (ja) | 2022-06-27 |
| CA3137450A1 (fr) | 2020-10-29 |
| EP3959314A1 (fr) | 2022-03-02 |
| CN114026233A (zh) | 2022-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55766A (fr) | Nanoparticules lipidiques | |
| EP3877522A4 (fr) | Formulations de nanoparticules lipidiques | |
| IL282995A (en) | Formulations of lipid nanoparticles | |
| DK3532103T3 (da) | Formuleringer af lipid-nanopartikler | |
| EP3645767A4 (fr) | Nanoparticules magnétiques | |
| EP3967649A4 (fr) | Nanoparticule lipidique | |
| EP2968510A4 (fr) | Compositions à base de nanoparticules | |
| EP3863965C0 (fr) | Nanomatériaux exfoliés par liquide | |
| DK3835287T3 (da) | Kationisk lipid | |
| JP2016502162A5 (fr) | ||
| EP2981285A4 (fr) | Nouvelles compositions de nanoparticules | |
| EP4201400A4 (fr) | Nanoparticule lipidique | |
| EP3887350A4 (fr) | Nanoparticules lipidiques solides de curcumine | |
| IL281425A (en) | Nanoparticle formulations | |
| IL283458A (en) | Nanoparticles comprising tacrolimus | |
| EP3668705C0 (fr) | Fabrication additive | |
| DK3946179T4 (da) | Stomiposer | |
| EP3558864A4 (fr) | Nanoparticules | |
| EP3986832A4 (fr) | Nanocomposites de polymère de polyester | |
| EP3534909A4 (fr) | Nanoparticules polymères | |
| EP3351561A4 (fr) | Dérivé d'adrénomédulline à action prolongée | |
| MA43648A (fr) | Conjugués de nanoparticules | |
| EP3830021A4 (fr) | Nanoparticules de tétrahexaèdre | |
| EP3512503A4 (fr) | Formulations liposomales | |
| PL3645513T3 (pl) | Pochodne benzoazepiny |